SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
January 18, 2022
Ryan Allway January 18th, 2022 The Dual-Site Study Will Be Conducted at the Hannover Medical School in Germany, and Israel’s Tel-Aviv Sourasky Medical Center TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of... Read more
